Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
30.99
+1.26 (4.24%)
Mar 14, 2025, 11:33 AM EDT - Market open
Viking Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -109.96 | -85.9 | -68.87 | -54.99 | -39.5 | |
Depreciation & Amortization | 0.35 | 0.29 | 0.29 | 0.3 | 0.28 | |
Other Amortization | 0.09 | 0.09 | 0.06 | 0.02 | 0.11 | |
Loss (Gain) From Sale of Investments | -17.38 | -8.2 | 1.22 | 3.91 | 3.77 | |
Stock-Based Compensation | 29.71 | 16.75 | 8.67 | 6.1 | 5.82 | |
Other Operating Activities | 0.04 | 0.04 | 0.04 | 0.01 | 0.03 | |
Change in Accounts Payable | 2.3 | -1.02 | 7.09 | -2.54 | 1.56 | |
Change in Other Net Operating Assets | 7.06 | 4.57 | 3.1 | -0.38 | 6.16 | |
Operating Cash Flow | -87.79 | -73.38 | -48.4 | -47.59 | -21.78 | |
Investment in Securities | -553.37 | -179.09 | 54.75 | 37.96 | 41.57 | |
Investing Cash Flow | -553.37 | -179.09 | 54.75 | 37.96 | 41.57 | |
Issuance of Common Stock | 654.57 | 278.5 | 12.51 | 7.63 | 1.27 | |
Repurchase of Common Stock | -42.1 | -7.12 | -8.33 | -0.71 | -0.3 | |
Other Financing Activities | - | - | -0.02 | -0.05 | -0.03 | |
Financing Cash Flow | 612.46 | 271.38 | 4.16 | 6.88 | 0.95 | |
Foreign Exchange Rate Adjustments | -0.15 | -0.03 | -0.26 | - | - | |
Net Cash Flow | -28.84 | 18.88 | 10.26 | -2.75 | 20.74 | |
Free Cash Flow | -87.79 | -73.38 | -48.4 | -47.59 | -21.78 | |
Free Cash Flow Per Share | -0.81 | -0.78 | -0.63 | -0.62 | -0.30 | |
Levered Free Cash Flow | -55.58 | -42.36 | -25.22 | -32.16 | -15.06 | |
Unlevered Free Cash Flow | -55.61 | -42.4 | -25.24 | -32.16 | -15.1 | |
Change in Net Working Capital | -8.66 | -3.58 | -9.76 | 3.76 | -5.47 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.